NCT05599191: An ongoing trial by Bellus Health Inc. - a GSK company
This trial is ongoing. It must report results 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05599191 |
|---|---|
| Title | A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 25, 2022 |
| Completion date | Dec. 18, 2025 |
| Required reporting date | Dec. 18, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 12, 2026 |
| Days late | None |